Navigation Links
PathoGenetix Hires Technology Development VP for Resolution Microbial Genotyping System
Date:6/18/2013

Woburn, MA (PRWEB) June 18, 2013

PathoGenetix, Inc., a commercial-stage developer of an automated system for rapid bacterial strain typing, announced today that John A. Luckey, Ph.D., M.B.A., has joined the company as Vice President of Engineering. Dr. Luckey will lead technology development and integration for the company’s RESOLUTION™ Microbial Genotyping System. The fully automated RESOLUTION System, which includes the benchtop instrument, pathogen-specific assay kits, database and software, will be commercially available in 2014 for use in food safety testing and foodborne illness outbreak investigations.

Dr. Luckey has more than 20 years of experience in biotechnology systems research and development with both large and small diagnostic companies. Prior to joining PathoGenetix, he was Technical Projects Director with Roche NimbleGen, working with the Applied Science and Molecular Diagnostics divisions, and Director of Platform Development, directing research and development for the company’s core DNA microarray synthesis technology. Prior to Roche, Dr. Luckey managed software development and instrumentation design engineering activities at OpGen Technologies, and product development, engineering and molecular biology projects at MJ Research. In 1994, he founded GeneSys Technologies to market the BaseStation DNA Fragment Analyzer, an ultrathin gel electrophoresis system that he had designed, developed and patented. Dr. Luckey holds a Ph.D. in Analytical Chemistry and an M.B.A. in Executive Management from the University of Wisconsin, Madison.

“We are fortunate to bring John Luckey to PathoGenetix at this exciting time. His extensive background and experience with commercializing bioanalytical instrumentation systems are a great match for our task of bringing the RESOLUTION System to market—first in food safety, and then to strategic follow-on opportunities as well,” said Ann Merrifield, President and CEO of PathoGenetix.

The RESOLUTION System is based on PathoGenetix’s proprietary Genome Sequence Scanning™ (GSS™) technology, initially developed to detect bio-threat pathogens in environmental samples under a five-year, $50-million contract through the Department of Homeland Security. The breakthrough genotyping technology isolates and analyzes DNA direct from complex mixtures such as enriched food samples—without the need for a pure culture isolate—and provides molecular serotype and strain type information for target bacteria in just five hours. The strain type information provided by GSS is comparable in resolution to pulsed field gel electrophoresis (PFGE), the current standard for pathogen identification.

“I am excited to join such a talented and dynamic team committed to serving the growing needs of the food safety industry. I look forward to leading PathoGenetix’s efforts to bring its breakthrough GSS technology to this market and to others in the future,” said Dr. Luckey.

Performance testing and submission to AOAC of the RESOLUTION instrument, assays kits and protocols is planned for 2014. PathoGenetix is a sustaining member of the International Association for Food Protection (IAFP) and will be displaying the RESOLUTION System at the 2013 IAFP Annual Meeting, July 28-31 in Charlotte, NC.

About PathoGenetix, Inc.

PathoGenetix, Inc. is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. PathoGenetix is a venture-backed company that has received more than $50 million in technology development funding from the Department of Homeland Security. The core GSS technology isolates and analyzes DNA directly from an enriched biological sample—without the need for a cultured isolate—and provides results in just five hours, days faster than current methods. GSS has broad applicability in food safety, industrial microbiology, and clinical diagnostics and research. The first commercial GSS system will be available in 2014 for use in food safety testing and foodborne illness outbreak investigations. Learn more at http://www.pathogenetix.com.

Read the full story at http://www.prweb.com/releases/Luckey/Genotyping/prweb10843405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
2. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
3. PathoGenetix Adds Director of Manufacturing and Begins Production of New Rapid Bacterial Strain Typing System
4. PathoGenetix Hires Food Safety Testing Expert John W. Czajka as Vice President of Business Development
5. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
6. Avenida Suites Hires Director for Global Business Development
7. InspireMD Hires Vice President of Corporate Development
8. AFcell Medical Hires Chief Operating Officer
9. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
10. PI hires William Culpi as Engineering Chief - PI miCos USA Products by PI USA
11. InSoCal CONNECT Hires Technology Talent Executive Carol Caldwell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... York , March 22, 2017 ... largely fragmented, states a research report by Transparency Market ... Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted for ... 2015. The prominent players in this market are focusing ... their product portfolio, which is likely to lead to ...
(Date:3/22/2017)...   Boston Biomedical , an industry leader in ... cancer stemness pathways, today announced its Board of Directors ... Executive Officer, effective April 24, 2017. ... M.D., FACP, who has led Boston Biomedical since he ... Boston Biomedical has grown from a "garage startup" without ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has ... part of their live events series, “Stem Cell Therapy: The Next Phase in the ... the 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design Innovations ... goal and raising over $30,000 in the first 40 minutes of crowdfunding. EcoQube ... herbs fast, easy, and affordably, anywhere. , “Simply add fertilized water and in ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
Breaking Biology News(10 mins):